Company intelligence / Profile preview

Dragonfly Dreamers

Waltham, MA, United Statesdragonflydreamers.blogspot.com ↗

Ownership: Private
Development stage: Other

Overview

Dragonfly has multiple clinical-stage assets including DF9001 and DF6215. DF9001 is an EGFR-targeting TriNKET® being evaluated for advanced solid tumors. DF6215 is an engineered IL2Rα-active agonist cytokine. The company previously partnered with Bristol Myers Squibb on the IL12 cytokine program DF6002; rights have since returned to Dragonfly. Early results are encouraging for immune engagement and anti-tumor activity in solid tumor indications.

Therapeutic areas: OncologyImmunologyOtherNeurologyInfectious Diseases
Modalities: Monoclonal antibodyBispecific monoclonal antibodyCytokineRecombinant fusion proteinSmall molecule
Industry: Biotech

Partnerships

Merck & Co.AbbVieGilead SciencesBristol Myers Squibb

Beyond the preview

Go deeper on Dragonfly Dreamers.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dragonfly Dreamers.

Explore the full profile